JPWO2022165258A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022165258A5 JPWO2022165258A5 JP2023544261A JP2023544261A JPWO2022165258A5 JP WO2022165258 A5 JPWO2022165258 A5 JP WO2022165258A5 JP 2023544261 A JP2023544261 A JP 2023544261A JP 2023544261 A JP2023544261 A JP 2023544261A JP WO2022165258 A5 JPWO2022165258 A5 JP WO2022165258A5
- Authority
- JP
- Japan
- Prior art keywords
- hhla2
- seq
- amino acid
- acid sequence
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 claims description 80
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 claims description 78
- 239000011230 binding agent Substances 0.000 claims description 56
- 239000000427 antigen Substances 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 239000012642 immune effector Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 101000945493 Homo sapiens Killer cell immunoglobulin-like receptor 3DL3 Proteins 0.000 claims description 4
- 102100034834 Killer cell immunoglobulin-like receptor 3DL3 Human genes 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000050245 human HHLA2 Human genes 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000012925 reference material Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142832P | 2021-01-28 | 2021-01-28 | |
| US63/142,832 | 2021-01-28 | ||
| PCT/US2022/014423 WO2022165258A1 (en) | 2021-01-28 | 2022-01-28 | Hhla2 binding agents with novel activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024509501A JP2024509501A (ja) | 2024-03-04 |
| JP2024509501A5 JP2024509501A5 (https=) | 2025-02-04 |
| JPWO2022165258A5 true JPWO2022165258A5 (https=) | 2025-02-04 |
Family
ID=82652818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544261A Pending JP2024509501A (ja) | 2021-01-28 | 2022-01-28 | 新規活性を持つｈｈｌａ２結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250270323A1 (https=) |
| EP (1) | EP4284431A4 (https=) |
| JP (1) | JP2024509501A (https=) |
| KR (1) | KR20230135637A (https=) |
| CN (1) | CN116981476A (https=) |
| AU (1) | AU2022214939A1 (https=) |
| BR (1) | BR112023014826A2 (https=) |
| CA (1) | CA3207494A1 (https=) |
| IL (1) | IL304584A (https=) |
| MX (1) | MX2023008182A (https=) |
| WO (1) | WO2022165258A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326764A (en) * | 2023-09-08 | 2026-04-01 | Nextpoint Therapeutics Inc | Antibody-drug conjugates |
| CN119841949A (zh) * | 2023-10-17 | 2025-04-18 | 科辉智药(深圳)新药研究中心有限公司 | 一种抗人hhla2的纳米抗体及其应用 |
| CN121005781A (zh) * | 2024-05-24 | 2025-11-25 | 合肥天港免疫药物有限公司 | 高亲和力b7h7抗体或其抗原结合片段及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10280208B2 (en) * | 2014-04-30 | 2019-05-07 | Albert Einstein College Of Medicine | TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies |
| EA202090003A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка |
| KR20210007959A (ko) * | 2018-04-06 | 2021-01-20 | 다나-파버 캔서 인스티튜트 인크. | Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도 |
-
2022
- 2022-01-28 WO PCT/US2022/014423 patent/WO2022165258A1/en not_active Ceased
- 2022-01-28 CA CA3207494A patent/CA3207494A1/en active Pending
- 2022-01-28 MX MX2023008182A patent/MX2023008182A/es unknown
- 2022-01-28 BR BR112023014826A patent/BR112023014826A2/pt unknown
- 2022-01-28 CN CN202280012137.1A patent/CN116981476A/zh active Pending
- 2022-01-28 KR KR1020237028708A patent/KR20230135637A/ko active Pending
- 2022-01-28 EP EP22746752.9A patent/EP4284431A4/en active Pending
- 2022-01-28 US US18/263,313 patent/US20250270323A1/en active Pending
- 2022-01-28 JP JP2023544261A patent/JP2024509501A/ja active Pending
- 2022-01-28 AU AU2022214939A patent/AU2022214939A1/en active Pending
-
2023
- 2023-07-19 IL IL304584A patent/IL304584A/en unknown